ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.03

+0.8%

Nov 28 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (440)	10/3/2007 3:22:06 PM
From: mopgcw	of 588

Citi: ACADIA Pharmaceuticals Inc (ACAD) Initiation of Initiating with a Hold (2S) Rating and $19 Price Target coverage Y * Potential partnership only catalyst over next 12-months - Despite having mulitple shots on goal with two clinical drug candidates, there will not be any data released over the next year and the only potential catalyst will be a partnership for Pimavanserin. While we believe Pimavanserin Phase II data for co-therapy in schizophrenia will enable Acadia to find a partner, expectations for a partnership are largely priced into the stock. Therefore, there may be limited upside to the stock at current levels over the next twelve months unless a partnership with a major pharmaceutical company is announced. * Pimavanserin Phase II schizophrenia data with Risperdal promising, but unclear if it will translate to other atypical antipsychotic drugs - Pimavanserin may provide comparable efficacy but fewer side effects by enabling patients to use lower doses of current atypical antipsychotics when combined with Pimavanserin. Based on independent studies, we believe additional Phase II work may need to be conducted before a pivotal Phase III program can begin. * Pimavanserin targets underserved Parkinson's Disease Psychosis (PDP) Market - Theoretically, Pimavanserin should demonstrate a benefit in PDP but other antipsychotics have had difficulty obtaining clinical success in trials. * ACP-104 for monotherapy in schizophrenia is an exciting program and Phase IIb results expected 2H08 will help delineate its efficacy and safety profile

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next